Table 1.

List of included studies. The data of each randomized controlled trial is represented in the columns. NSCLC = Non-small cell lung cancer, ZA = Zoledronic Acid, SR-89 = Strontium-89, SC = Subcutaneous, IV = Intravenous, MBq = Megabecquerel.

Authors	Year	Primary cancer	Time of treatment compared to the main therapy	Treatment	Population size for treatment (n)	Comparator	Population size for comparator (n)
Barrett-Lee, P[33]	2014	Breast cancer	During	ZA- 4 mg/ 4 weeks	699	Ibandronic acid- 50 mg daily	705
Broom, R. J [34]	2015	Renal cell carcinoma	Before	Everolimus and ZA - 4 mg/ 4 weeks	15	Everolimus- 10 mg daily	15
Choudhury, K. B [31]	2011	NSCLC + others	During	ZA − 4 mg/ 4 weeks	60	1. Ibandronate- 6 mg/ 4 weeks 2. Pamidronate- 90 mg/ 4 weeks	1. 65 2. 62
Cleeland, C. S [76]	2013	Breast cancer	Before	ZA − 4mg/ 4 weeks + SC placebo	1020	Denosumab- 120 mg/ 4 weeks + IV placebo	1026
Fizazi, K [35]	2011	Prostate cancer	After	ZA − 4 mg/ 4 weeks + SC placebo	951	Denosumab- 120 mg/ 4 weeks + IV placebo	950
Francini, F [36]	2011	NSCLC	During	ZA − 4mg/ 4 weeks	28	Ibandronic acid- 50 mg/day	27
Henry, D [37]	2014	NSCLC	Before	ZA - 4 mg/ 4 weeks + SC placebo	797	Denosumab SC- 120 mg/ 4 weeks with placebo IV	800
Hilton, J. F [38]	2018	Breast cancer	After	ZA − 4 mg/ 4 weeks	38	Pamidronate	35
Jacobs, C [39]	2016	Breast cancer	During	ZA − 4 mg/ 4 weeks	35	Pamidronate	38
James, N [40]	2016	Prostate cancer	Before	Docetaxel, ZA − 4 mg/ 4 weeks	188	1. Docetaxel- 75 mg/m2/ 3 weeks, 2. Docetaxel and ZA 3. Docetaxel + Sr-89.	1. 191 2. 188 3. 190
Kamba, T [41]	2016	Prostate cancer	Before	ZA − 4 mg/ 4 weeks with combined androgen blockade	115	80 mg of bicalutamide orally once a day and subcutaneous luteinizing hormone–releasing hormone agonist every 4 or 12 weeks	112
Kohno, N [42]	2005	Breast cancer	During	ZA − 4 mg/ 4 weeks	114	Placebo	114
Martin, M [43]	2012	Breast cancer	Before	ZA − 4 mg/ 4 weeks + SC placebo	1020	Denosumab- 120 mg/ 4 weeks + IV placebo	1026
Murakami, H [44]	2014	NSCLC	After	ZA − 4 mg/ 4 weeks with Docetaxel	50	Docetaxel- 60 mg/m2	50
Pan, Y [45]	2014	Prostate cancer	After	Docetaxel-based chemotherapy + ZA - 4 mg/ 3 weeks	53	Docetaxel-based chemotherapy- 75 mg/m2 of docetaxel for 21 days and placebo	52
Pandya, K. J [56]	2010	NSCLC	After	Docetaxel, Carboplatin and ZA − 4 mg/ 4 weeks	64	Docetaxel- 75 mg/m2 for 1 h and carboplatin- IV for 15 min	64
Price, N [32]	1999	NSCLC + others	Before	ZA - A. 4 mg / 3 weeks B. 8 mg/ 3 weeks; reduced to 4 mg/ 3 weeks	A. 254 B. 265	Placebo	247
Rosen, L. S [46]	2003	Multiple myeloma and breast cancer	During	ZA - A. 4 mg/ 4 weeks B. 8 mg/ 4 weeks; later switched to 4 mg/ 4 weeks	A. 564 B. 526	Pamidronate- 90 mg/ 3 or 4 weeks	558
Rosen, L. S [47]	2004	NSCLC + others	During	ZA - A. 4 mg/ 4 weeks B. 8 mg/ 4 weeks; later switched to 4 mg/ 4 weeks	A. 257 B. 266	Placebo	250
Saad, F [48]	2002	Prostate cancer	During	ZA - A. 4 mg / 4 weeks B. 8 mg/ 4 weeks;later switched to 4 mg/ 4 weeks	A. 214 B. 221	Placebo	208
Smith, M. R [50]	2014	Prostate cancer	Before	ZA − 4 mg/ 4 weeks	323	Placebo	322
Smith, M. R. [49]	2015	Prostate cancer	After	ZA − 4 mg/ 4 weeks	951	Denosumab- 120 mg/ 4 weeks	950
Stopeck, A.T [51]	2010	Breast cancer	During	ZA − 4 mg/ 4 weeks + SC placebo	1020	Denosumab- 120 mg/ 4 weeks + IV placebo	1026
Ueno, S [52]	2013	Prostate cancer	Before	ZA − 4 mg/ 4 weeks with combined androgen blockade	29	Combined androgen blockade − 80 mg/ day	31
Wang, F [53]	2013	Prostate cancer	Before	ZA − 4 mg/ 4 weeks	69	Clodronate- 1600 mg / day	68
Wang, Y [55]	2013	NSCLC	Before	Sr-89, 0.9 % sodium chloride and ZA − 4 mg/ 4 weeks	45	1. ZA − 4 mg every 3/4 weeks 2. Sr-89–150 MBq of Sr-89 every 6 months 3. Chemotherapy	1. 45 2. 45 3. 45
Zaghloul, MS [54]	2010	Bladder cancer	After	ZA − 4 mg/ 4 weeks	20	Placebo	20